You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 290 No. 8, August 27, 2003 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Neurology
 •Cerebrovascular Disease
 •Stroke
 •Arrhythmias
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Stroke Prevention in Atrial Fibrillation

Albert L. Waldo, MD

JAMA. 2003;290:1093-1095.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Atrial fibrillation is a relatively common clinical problem, affecting an estimated 2.3 million adults in the United States.1 The prevalence of atrial fibrillation increases with age; nearly 4% of persons aged 60 years or older and 9% of those aged 80 years or older have atrial fibrillation,1 and about half the patients in the United States with atrial fibrillation are older than 75 years.2 By the year 2050, the prevalence of atrial fibrillation is expected to increase about 2.5 fold, with most of that increase explained by the growing proportion of individuals living into their 80s and beyond.1

Until a therapy or therapies are found that reliably, effectively, and safely prevent its recurrence, the 2 most important clinical problems associated with atrial fibrillation are prevention of tachycardia-mediated cardiomyopathy and prevention of ischemic stroke. Although prevention of tachycardia-mediated cardiomyopathy should almost always be possible, prevention of ischemic . . . [Full Text of this Article]

Author Affiliation: Case Western Reserve University, University Hospitals of Cleveland, Cleveland, Ohio.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

A Risk Score for Predicting Stroke or Death in Individuals With New-Onset Atrial Fibrillation in the Community: The Framingham Heart Study
Thomas J. Wang, Joseph M. Massaro, Daniel Levy, Ramachandran S. Vasan, Philip A. Wolf, Ralph B. D'Agostino, Martin G. Larson, William B. Kannel, and Emelia J. Benjamin
JAMA. 2003;290(8):1049-1056.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Assessment of left atrial appendage function with transthoracic tissue Doppler echocardiography
Uretsky et al.
Eur J Echocardiogr 2009;10:363-371.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.